Liposome-enabled bufalin and doxorubicin combination therapy for trastuzumab-resistant breast cancer with a focus on cancer stem cells

References

• Ferlay J, Ervik M, Colombet M, et al. 2020. Global cancer observatory: cancer today. [online]. Lyon: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today
   Google Scholar
• Ullah M. Breast cancer: current perspectives on the disease status. Adv Exp Med Biol. 2019;1152:51–64.
   PubMed Web of Science ®Google Scholar
• Palomeras S, Ruiz-Martínez S, Puig T. Targeting breast cancer stem cells to overcome treatment resistance. Molecules. 2018;23(9):2193. doi: 10.3390/molecules23092193.
   PubMed Web of Science ®Google Scholar
• Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003;100(7):3983–3988. doi: 10.1073/pnas.0530291100.
   PubMed Web of Science ®Google Scholar
• Zeng X, Liu C, Yao J, et al. Breast cancer stem cells, heterogeneity, targeting therapies and therapeutic implications. Pharmacol Res. 2021;163:105320. doi: 10.1016/j.phrs.2020.105320.
   PubMed Web of Science ®Google Scholar
• Dittmer J. Breast cancer stem cells: Features, key drivers and treatment options. Semin Cancer Biol. 2018;53:59–74. doi: 10.1016/j.semcancer.2018.07.007.
   PubMed Web of Science ®Google Scholar
• Li W, Ma H, Zhang J, et al. Unraveling the roles of CD44/CD24 and ALDH1 as cancer stem cell markers in tumorigenesis and metastasis. Sci Rep. 2017;7(1):13856. doi: 10.1038/s41598-017-14364-2.
   PubMed Web of Science ®Google Scholar
• Qiu Y, Yang L, Liu H, et al. Cancer stem cell-targeted therapeutic approaches for overcoming trastuzumab resistance in HER2-positive breast cancer. Stem Cells. 2021;39(9):1125–1136. doi: 10.1002/stem.3381.
   PubMed Web of Science ®Google Scholar
• Gao Y, Tang M, Leung E, et al. Dual or multiple drug loaded nanoparticles to target breast cancer stem cells. RSC Adv. 2020;10(32):19089–19105. doi: 10.1039/d0ra02801k.
   PubMed Web of Science ®Google Scholar
• Krause M, Dubrovska A, Linge A, et al. Cancer stem cells: radioresistance, prediction of radiotherapy outcome and specific targets for combined treatments. Adv Drug Deliv Rev. 2017;109:63–73. doi: 10.1016/j.addr.2016.02.002.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Sun Y, Lu Y-Y, et al. Curcumin reduces mitomycin C resistance in breast cancer stem cells by regulating bcl-2 family-mediated apoptosis. Cancer Cell Int. 2017;17(1):84. doi: 10.1186/s12935-017-0453-3.
   PubMedGoogle Scholar
• Samson AAS, Park S, Kim SY, et al. Liposomal co-delivery-based quantitative evaluation of chemosensitivity enhancement in breast cancer stem cells by knockdown of GRP78/CLU. J Liposome Res. 2019;29(1):44–52. doi: 10.1080/08982104.2017.1420081.
   PubMed Web of Science ®Google Scholar
• Yang Z, Sun N, Cheng R, et al. Hybrid nanoparticles coated with hyaluronic acid lipoid for targeted co-delivery of paclitaxel and curcumin to synergistically eliminate breast cancer stem cells. J Mater Chem B. 2017;5(33):6762–6775. doi: 10.1039/c7tb01510k.
   PubMed Web of Science ®Google Scholar
• Zhang N, Liang X, Gao C, et al. Loading lovastatin into camptothecin-floxuridine conjugate nanocapsules for enhancing anti-metastatic efficacy of cocktail chemotherapy on triple-negative breast cancer. ACS Appl Mater Interfaces. 2018;10(35):29385–29397. doi: 10.1021/acsami.8b11723.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Liu L, Li F, et al. Salinomycin exerts anticancer effects on PC-3 cells and PC-3-derived cancer stem cells in vitro and in vivo. Biomed Res Int. 2017;2017:4101653. doi: 10.1155/2017/4101653.
   PubMed Web of Science ®Google Scholar
• Gao J, Liu J, Xie F, et al. Co-delivery of docetaxel and salinomycin to target both breast cancer cells and stem cells by plga/tpgs nanoparticles. Int J Nanomedicine. 2019;14:9199–9216. doi: 10.2147/IJN.S230376.
   PubMed Web of Science ®Google Scholar
• Sulaiman A, McGarry S, El-Sahli S, et al. Co-targeting bulk tumor and CSCs in clinically translatable TNBC patient-derived xenografts via combination nanotherapy. Mol Cancer Ther. 2019;18(10):1755–1764. doi: 10.1158/1535-7163.MCT-18-0873.
   PubMed Web of Science ®Google Scholar
• Saleh T, Bloukh S, Carpenter VJ, et al. Therapy-induced senescence: an “old” friend becomes the enemy. Cancers. 2020;12(4):822. doi: 10.3390/cancers12040822.
   PubMed Web of Science ®Google Scholar
• Tang M, Lozano Hernandez L, Reginald-Opara JN, et al. Zebularine suppressed gemcitabine-induced senescence and improved the cellular and plasma pharmacokinetics of gemcitabine, augmented by liposomal co-delivery. Int J Pharm. 2021;602:120659. doi: 10.1016/j.ijpharm.2021.120659.
   PubMedGoogle Scholar
• Rommasi F, Esfandiari N. Liposomal nanomedicine: applications for drug delivery in cancer therapy. Nanoscale Res Lett. 2021;16(1):95.
   PubMed Web of Science ®Google Scholar
• Golombek SK, May JN, Theek B, et al. Tumor targeting via EPR: strategies to enhance patient responses. Adv Drug Deliv Rev. 2018;130:17–38. doi: 10.1016/j.addr.2018.07.007.
   PubMed Web of Science ®Google Scholar
• Kanamala M, Wilson WR, Yang M, et al. Mechanisms and biomaterials in pH-responsive tumour targeted drug delivery: a review. Biomaterials. 2016;85:152–167. doi: 10.1016/j.biomaterials.2016.01.061.
   PubMed Web of Science ®Google Scholar
• Maadi H, Soheilifar MH, Choi WS, et al. Trastuzumab mechanism of action; 20 years of research to unravel a dilemma. Cancers. 2021;13(14):3540. doi: 10.3390/cancers13143540.
   PubMed Web of Science ®Google Scholar
• Rodríguez CE, Berardi DE, Abrigo M, et al. Breast cancer stem cells are involved in trastuzumab resistance through the HER2 modulation in 3D culture. J Cell Biochem. 2018;119(2):1381–1391. doi: 10.1002/jcb.26298.
   PubMed Web of Science ®Google Scholar
• Li R-J, Ying X, Zhang Y, et al. All-trans retinoic acid stealth liposomes prevent the relapse of breast cancer arising from the cancer stem cells. J Control Release. 2011;149(3):281–291. doi: 10.1016/j.jconrel.2010.10.019.
   PubMed Web of Science ®Google Scholar
• Wang H, Zhang H, Zhu Y, et al. Anticancer mechanisms of salinomycin in breast cancer and its clinical applications. Front Oncol. 2021;11:654428. doi: 10.3389/fonc.2021.654428.
   PubMed Web of Science ®Google Scholar
• Qi D, Liu Y, Li J, et al. Salinomycin as a potent anticancer stem cell agent: state of the art and future directions. Med Res Rev. 2022;42(3):1037–1063. doi: 10.1002/med.21870.
   PubMed Web of Science ®Google Scholar
• Wang J, Xia Y, Zuo Q, et al. Molecular mechanisms underlying the antimetastatic activity of bufalin. Mol Clin Oncol. 2018;8(5):631–636. doi: 10.3892/mco.2018.1591.
   PubMed Web of Science ®Google Scholar
• Chen F, Li ZHU, Junyan HU, et al. Bufalin attenuates triple‑negative breast cancer cell stemness by inhibiting the expression of SOX2/OCT4. Oncol Lett. 2020;20(5):171–171. doi: 10.3892/ol.2020.12028.
   PubMed Web of Science ®Google Scholar
• Soumoy L, Ghanem GE, Saussez S, et al. Bufalin for an innovative therapeutic approach against cancer. Pharmacol Res. 2022;184:106442. doi: 10.1016/j.phrs.2022.106442.
   PubMed Web of Science ®Google Scholar
• Gao Y, Shelling AN, Porter D, et al. Stability of trastuzumab during nanomedicine formulation using SEC-HPLC coupled with polyacrylamide gel electrophoresis. Pharm Dev Technol. 2023;28(3–4):288–298. doi: 10.1080/10837450.2023.2191277.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Alonso P, Cristobal I, Zazo S, et al. Recent insights into the development of preclinical trastuzumab-resistant HER2+ breast cancer models. Curr Med Chem. 2018;25(17):1976–1998. doi: 10.2174/0929867323666161216144659.
   PubMed Web of Science ®Google Scholar
• Zazo S, González-Alonso P, Martín-Aparicio E, et al. Generation, characterization, and maintenance of trastuzumab-resistant HER2+ breast cancer cell lines. Am J Cancer Res. 2016;6(11):2661–2678.
   PubMed Web of Science ®Google Scholar
• Tang M, Svirskis D, Leung E, et al. Can intracellular drug delivery using hyaluronic acid functionalised pH-sensitive liposomes overcome gemcitabine resistance in pancreatic cancer? J Control Release. 2019;305:89–100. doi: 10.1016/j.jconrel.2019.05.018.
   PubMed Web of Science ®Google Scholar
• O’Brien NA, Browne BC, Chow L, et al. Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib. Mol Cancer Ther. 2010;9(6):1489–1502. doi: 10.1158/1535-7163.MCT-09-1171.
   PubMed Web of Science ®Google Scholar
• Lombardo Y, de Giorgio A, Coombes CR, et al. Mammosphere formation assay from human breast cancer tissues and cell lines. J Vis Exp. 2015;97:52671. doi: 10.3791/52671.
   PubMed Web of Science ®Google Scholar
• Chou T-C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70(2):440–446. doi: 10.1158/0008-5472.CAN-09-1947.
   PubMed Web of Science ®Google Scholar
• Chou T. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58(3):621–681. doi: 10.1124/pr.58.3.10.
   PubMed Web of Science ®Google Scholar
• Wang F, Dai W, Wang Y, et al. The synergistic in vitro and in vivo antitumor effect of combination therapy with salinomycin and 5-Fluorouracil against hepatocellular carcinoma. PLOS One. 2014;9(5):e97414. doi: 10.1371/journal.pone.0097414.
   PubMed Web of Science ®Google Scholar
• Zhang R, Yang J, Sima M, et al. Sequential combination therapy of ovarian cancer with degradable N-(2-hydroxypropyl)methacrylamide copolymer paclitaxel and gemcitabine conjugates. Proc Natl Acad Sci USA. 2014;111(33):12181–12186. doi: 10.1073/pnas.1406233111.
   PubMed Web of Science ®Google Scholar
• Ishida T, Okada Y, Kobayashi T, et al. Development of pH-sensitive liposomes that efficiently retain encapsulated doxorubicin (DXR) in blood. Int J Pharm. 2006;309(1–2):94–100. doi: 10.1016/j.ijpharm.2005.11.010.
   PubMedGoogle Scholar
• Zhang W, Wang G, Falconer JR, et al. Strategies to maximize liposomal drug loading for a poorly water-soluble anticancer drug. Pharm Res. 2015;32(4):1451–1461. doi: 10.1007/s11095-014-1551-8.
   PubMed Web of Science ®Google Scholar
• Wang Y, Shen SY, Liu L, et al. Jolkinolide B inhibits proliferation or migration and promotes apoptosis of MCF-7 or BT-474 breast cancer cells by downregulating the PI3K-Akt pathway. J Ethnopharmacol. 2022;282:114581. doi: 10.1016/j.jep.2021.114581.
   PubMed Web of Science ®Google Scholar
• Clynes RA, Towers TL, Presta LG, and, al, et. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med. 2000;6(4):443–446. doi: 10.1038/74704.
   PubMed Web of Science ®Google Scholar
• Valabrega G, Montemurro F, Aglietta M. Transtuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol. 2007;18(6):977–984. doi: 10.1093/annonc/mdl475.
   PubMed Web of Science ®Google Scholar
• Mittendorf E, Wu Y, Scaltriti M, et al. Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Clin Cancer Res. 2009;15(23):7381–7388. doi: 10.1158/1078-0432.CCR-09-1735.
   PubMed Web of Science ®Google Scholar
• Jin J, Krishnamachary B, Mironchik Y, et al. Phototheranostics of CD44-positive cell populations in triple negative breast cancer. Sci Rep. 2016;6(1):27871. doi: 10.1038/srep27871.
   PubMedGoogle Scholar
• Boulbes DR, Chauhan GB, Jin Q, et al. CD44 expression contributes to trastuzumab resistance in HER2-positive breast cancer cells. Breast Cancer Res Treat. 2015;151(3):501–513. doi: 10.1007/s10549-015-3414-3.
   PubMed Web of Science ®Google Scholar
• Dhillon J, Astanehe A, Lee C, et al. The expression of activated Y-box binding protein-1 serine 102 mediates trastuzumab resistance in breast cancer cells by increasing CD44+ cells. Oncogene. 2010;29(47):6294–6300. doi: 10.1038/onc.2010.365.
   PubMed Web of Science ®Google Scholar
• Nami B, Wang Z. HER2 in breast cancer stemness: a negative feedback loop towards trastuzumab resistance. Cancers. 2017;9(5):40. doi: 10.3390/cancers9050040.
   PubMed Web of Science ®Google Scholar
• Oliveras-Ferraros C, Corominas-Faja B, Cufí S, et al. Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (herceptin). Cell Cycle. 2012;11(21):4020–4032. doi: 10.4161/cc.22225.
   PubMed Web of Science ®Google Scholar
• Korkaya H, Paulson A, Iovino F, et al. HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene. 2008;27(47):6120–6130. doi: 10.1038/onc.2008.207.
   PubMed Web of Science ®Google Scholar
• Ottewell D, Theillet C, Vivekanandhan S, et al. Resistance to trastuzumab. Cancers. 2022;14(20):5115. doi: 10.3390/cancers14205115.
   PubMed Web of Science ®Google Scholar
• McDermott MSJ, Conlon N, Browne BC, et al. HER2-targeted tyrosine kinase inhibitors cause therapy-induced-senescence in breast cancer cells. Cancers. 2019;11(2):197. doi: 10.3390/cancers11020197.
   PubMed Web of Science ®Google Scholar
• Tari AM, Lim SJ, Hung MC, et al. Her2/neu induces all-trans retinoic acid (ATRA) resistance in breast cancer cells. Oncogene. 2002;21(34):5224–5232. doi: 10.1038/sj.onc.1205660.
   PubMed Web of Science ®Google Scholar
• Liu y, Yu F, Dai S, et al. All-trans retinoic acid and doxorubicin delivery by folic acid modified polymeric micelles for the modulation of Pin1-mediated dox-induced breast cancer stemness and metastasis. Mol Pharm. 2021;18(11):3966–3978. doi: 10.1021/acs.molpharmaceut.1c00220.
   PubMedGoogle Scholar
• Sun R, Liu Y, Li SY, et al. Co-delivery of all-trans-retinoic acid and doxorubicin for cancer therapy with synergistic inhibition of cancer stem cells. Biomaterials. 2015;37:405–414. doi: 10.1016/j.biomaterials.2014.10.018.
   PubMed Web of Science ®Google Scholar
• Li J, Xu WQ, Yuan XL, et al. Polymer-lipid hybrid anti-HER2 nanoparticles for targeted salinomycin delivery to HER2-positive breast cancer stem cells and cancer cells. Int J Nanomedicine. 2017;12:6909–6921. doi: 10.2147/IJN.S144184.
   PubMed Web of Science ®Google Scholar
• Li Y, Tian X, Liu X, et al. Bufalin inhibits human breast cancer tumorigenesis by inducing cell death through the ROS-mediated RIP1/RIP3/PARP-1 pathways. Carcinogenesis. 2018;39(5):700–707. doi: 10.1093/carcin/bgy039.
   PubMed Web of Science ®Google Scholar
• Yuan ZT, Shi XJ, Yuan YX, et al. Bufalin reverses ABCB1-mediated drug resistance in colorectal cancer. Oncotarget. 2017;8(29):48012–48026. doi: 10.18632/oncotarget.18225.
   PubMedGoogle Scholar
• Zhang C, Fu L. Effects of bufalin combined with doxorubicin on the proliferation and apoptosis of human lung cancer cell line A549 in vitro. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2017;42(7):762–768. doi: 10.11817/j.issn.1672-7347.2017.07.004.
   PubMedGoogle Scholar
• Chen J, Lu WL, Gu W, et al. Drug-in-cyclodextrin-in-liposomes: a promising delivery system for hydrophobic drugs. Expert Opin Drug Deliv. 2014;11(4):565–577. doi: 10.1517/17425247.2014.884557.
   PubMed Web of Science ®Google Scholar
• Lin E-Y, Chen Y-S, Li Y-S, et al. Liposome consolidated with cyclodextrin provides prolonged drug retention resulting in increased drug bioavailability in brain. Int J Mol Sci. 2020;21(12):4408. doi: 10.3390/ijms21124408.
   PubMed Web of Science ®Google Scholar
• Wu J. The enhanced permeability and retention (EPR) effect: the significance of the concept and methods to enhance its application. J Pers Med. 2021;11(8):771. doi: 10.3390/jpm11080771.
   PubMed Web of Science ®Google Scholar
• Di J, Gao X, Du Y, et al. Size, shape, charge and “stealthy” surface: Carrier properties affect the drug circulation time in vivo. Asian J Pharm Sci. 2021;16(4):444–458. doi: 10.1016/j.ajps.2020.07.005.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Tian Z, Zhao X, et al. Dual-modified bufalin loaded liposomes for enhanced tumor targeting. Colloids Surf A. 2019;571:72–79. doi: 10.1016/j.colsurfa.2019.03.060.
   Google Scholar
• Alyane M, Barratt G, Lahouel M. Remote loading of doxorubicin into liposomes by transmembrane pH gradient to reduce toxicity toward H9c2 cells. Saudi Pharm J. 2016;24(2):165–175. doi: 10.1016/j.jsps.2015.02.014.
   PubMed Web of Science ®Google Scholar
• Bolotin EM, Cohen R, Bar LK, et al. Ammonium sulfate gradients for efficient and stable remote loading of amphipathic weak bases into liposomes and ligandoliposomes. J Liposome Res. 1994;4(1):455–479. doi: 10.3109/08982109409037057.
   Google Scholar
• Chen H, Gao J, Wang F, et al. Preparation, characterization and pharmacokinetics of liposomes-encapsulated cyclodextrins inclusion complexes for hydrophobic drugs. Drug Deliv. 2007;14(4):201–208. doi: 10.1080/10717540601036880.
   PubMed Web of Science ®Google Scholar
• Rehman A, Omran Z, Anton H, et al. Development of doxorubicin hydrochloride loaded pH-sensitive liposomes: investigation on the impact of chemical nature of lipids and liposome composition on pH-sensitivity. Eur J Pharm Biopharm. 2018;133:331–338. doi: 10.1016/j.ejpb.2018.11.001.
   PubMed Web of Science ®Google Scholar
• Zhang W, Wang G, See E, et al. Post-insertion of poloxamer 188 strengthened liposomal membrane and reduced drug irritancy and in vivo precipitation, superior to PEGylation. J Control Release. 2015;203:161–169. doi: 10.1016/j.jconrel.2015.02.026.
   PubMed Web of Science ®Google Scholar
• Ding L, Yang Y, Lu Q, et al. Bufalin inhibits tumorigenesis, stemness, and epithelial–mesenchymal transition in colorectal cancer through a C-kit/slug signaling axis. Int J Mol Sci. 2022;23(21):13354. doi: 10.3390/ijms232113354.
   PubMed Web of Science ®Google Scholar
• Irene B, Claudio M. Doxorubicin and α-Mangostin oppositely affect luminal breast cancer cell stemness evaluated by a new retinaldehyde-dependent ALDH assay in MCF-7 tumor spheroids. Biomed Pharmacother. 2020;124:109927.
   PubMed Web of Science ®Google Scholar
• Geng T, Tang M, Yee Paek S, et al. A simple approach to re-engineering small extracellular vesicles to circumvent endosome entrapment. Int J Pharm. 2022;626:122153. doi: 10.1016/j.ijpharm.2022.122153.
   PubMedGoogle Scholar
• Fulton M, Najahi-Missaoui W. Liposomes in cancer therapy: how did we start and where are we now. Int J Mol Sci. 2023;24(7):6615. doi: 10.3390/ijms24076615.
   PubMed Web of Science ®Google Scholar
• Rossi F, Noren H, Jove R, et al. Differences and similarities between cancer and somatic stem cells: therapeutic implications. Stem Cell Res Ther. 2020;11(1):489. doi: 10.1186/s13287-020-02018-6.
   PubMed Web of Science ®Google Scholar
• Qian L, Su H, Wang G, et al. Anti-tumor activity of bufalin by inhibiting c-MET mediated MEK/ERK and PI3K/AKT signaling pathways in gallbladder cancer. J Cancer. 2020;11(11):3114–3123. doi: 10.7150/jca.38393.
   PubMed Web of Science ®Google Scholar
• Bandyopadhyay A, Wang L, Agyin J, et al. Doxorubicin in combination with a small TGFβ inhibitor: a potential novel therapy for metastatic breast cancer in mouse models. PLOS One. 2010;5(4):e10365. doi: 10.1371/journal.pone.0010365.
   PubMed Web of Science ®Google Scholar
• Novikov N, Zolotaryova S, Gautreau A, et al. Mutational drivers of cancer cell migration and invasion. Br J Cancer. 2021;124(1):102–114. doi: 10.1038/s41416-020-01149-0.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Torres M, Allan AL. Aldehyde dehydrogenase as a marker and functional mediator of metastasis in solid tumors. Clin Exp Metastasis. 2016;33(1):97–113. doi: 10.1007/s10585-015-9755-9.
   PubMed Web of Science ®Google Scholar
• Wu J. S, Jiang J, Chen B. J, et al. Plasticity of cancer cell invasion: patterns and mechanisms. Transl Oncol. 2021;14(1):100899. doi: 10.1016/j.tranon.2020.100899.
   PubMed Web of Science ®Google Scholar
• Karnoub A, Dash A, Vo A, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature. 2007;449(7162):557–563. doi: 10.1038/nature06188.
   PubMed Web of Science ®Google Scholar